Eyes Down For AstraZeneca plc Results

It’s first-half time for drugs giant AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazenecaWe haven’t had any results from AstraZeneca (LSE: AZN) (NYSE: AZN.US) since the failed takeover bid to see how things are going, but there will be many eyes, including Pfizer‘s no doubt, focused on first-half figures when we get them on Thursday 31 July.

The City is still forecasting a 15% drop in earnings per share (EPS) for the full year to December, but AstraZeneca has given us tantalising hints that a return to profit growth might actually happen before 2016 as many observers expect.

No surprises

At year-end 2013, the company did say that “Core EPS for 2014 is expected to decline in the teens at CER“, and that fits in with predictions, but we also heard that it “expects revenues in 2017 will be broadly in line with 2013“. That would amount to a healthy reversal after 2013 ended with a 6% fall in revenue to $25.7bn and a 23% drop in core EPS.

Revenues are down largely due to recent loss of some patent protections and increased competition from generic drugs, so a renewed development pipeline is clearly the priority right now — as it has been since Pascal Soriot took over the top job.

Pipeline progress

And it appears to be bearing fruit, as the firm’s first-quarter update released in April told us of “significant progress made towards achieving scientific leadership in core therapeutic areas“.

The company says it is making impressively good progress with a large number of things with very strange names, including the start of Phase III trials for cancer drug Olaparib and arthritis treatment Brodalumab. And four other programmes are advancing to Phase III.

With revenue for the quarter actually up 3% at constant exchange rates, Mr Soriot said that “revenue growth reflects the increasing contribution from the five growth platforms that showed strong performance“.

Tricky valuation

Looking at AstraZeneca’s share price, it’s clearly still buoyed by the Pfizer effect. It soared and stayed close to the £50 level while a takeover was looking like a serious possibility, but since the attempt was called off the shares have not retreated to pre-bid levels. At £44.25 now, the price is still up 33% over 12 months and that puts the shares on a forward P/E of 17.5.

But long-term investors should be ignoring that and evaluating AstraZeneca on its own fundamental performance — and I’m optimistic about the forthcoming H1 update.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »